Organisation paid for research Program year 2023 Source: CMS Open Payments

Vanderbilt Univ

Neither a doctor nor a teaching hospital

Research payments

$271,906

4 payments

Through program year 2023, Vanderbilt Univ is reported as receiving $271,906 in research payments, across 4 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$23,608	1
2021	Research	$72,590	1
2020	Research	$18,974	1
2019	Research	$156,735	1

Breakdown

Who paid Research payments · program years 2019–2023

AstraZeneca Pharmaceuticals LP $156,735 1 payment
Novo Nordisk Inc $96,197 2 payments
Novartis Pharmaceuticals Corporation $18,974 1 payment

Studies the money was for Research payments · program years 2019–2023

Phase I II Study of Olaparib with Entinostat in the Treatement of Recurrent Platinum Resistant Homolgous Recombination Repair Proficient Ovarian Primary Peritoneal and Fallopian Tube Cancers $156,735 1 payment
Cardiovascular Effects of GLP-1 Receptor Activation $72,590 1 payment
Glucagon-like peptide-1 receptor agonist treatment in adult, obesity-related, symptomatic asthma $23,608 1 payment
A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the Mek $18,974 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.